Paraoxonase Variants Relate to 10-Year Risk in Coronary Artery DiseaseImpact of a High-Density Lipoprotein–Bound Antioxidant in Secondary Prevention
Jakub J. Regieli, MD*, ,
J. Wouter Jukema, MD, PhD , ,||,*,
Pieter A. Doevendans, MD, PhD*,
Aeilko H. Zwinderman, PhD#,
John J. Kastelein, MD, PhD**,
Diederick E. Grobbee, MD, PhD and
Yolanda van der Graaf, MD, PhD
* Department of Cardiology, University Medical Center Utrecht, Utrecht, the Netherlands
Juliuscenter for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, the Netherlands
Interuniversity Cardiology Institute of the Netherlands (ICIN/KNAW), Leiden, the Netherlands
Department of Cardiology, Leiden University Medical Center, Leiden, the Netherlands
|| Durrer Center for Cardiogenetic Research, Amsterdam, the Netherlands
# Department of Clinical Epidemiology, Academical Medical Center Amsterdam, Amsterdam, the Netherlands
** Department of Vascular Medicine, Academical Medical Center Amsterdam, Amsterdam, the Netherlands

View larger version (24K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 1 Temporal Patterns of 10-Year Risk by PON-1
Survival curves by paraoxonase-1 (PON-1) genotypes (A and B) methionine at codon 55 (M55L) and (C and D) glutamine at codon 192 (Q192R), vertically displaying cumulative absolute risk of death from (A and C) ischemic heart disease and (B and D) all-cause mortality. Follow-up time in years is displayed horizontally.
|
|
|